US6140466A
(en)
|
1994-01-18 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger protein derivatives and methods therefor
|
US20050084885A1
(en)
*
|
1994-01-18 |
2005-04-21 |
The Scripps Research Institute |
Zinc finger protein derivatives and methods therefor
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US7070934B2
(en)
*
|
1999-01-12 |
2006-07-04 |
Sangamo Biosciences, Inc. |
Ligand-controlled regulation of endogenous gene expression
|
US6599692B1
(en)
*
|
1999-09-14 |
2003-07-29 |
Sangamo Bioscience, Inc. |
Functional genomics using zinc finger proteins
|
US20020164575A1
(en)
*
|
1999-09-14 |
2002-11-07 |
Sangamo Biosciences, Inc., A Delaware Corporation |
Gene identification
|
US7329728B1
(en)
*
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
AU776576B2
(en)
*
|
1999-12-06 |
2004-09-16 |
Sangamo Biosciences, Inc. |
Methods of using randomized libraries of zinc finger proteins for the identification of gene function
|
US20020061512A1
(en)
*
|
2000-02-18 |
2002-05-23 |
Kim Jin-Soo |
Zinc finger domains and methods of identifying same
|
GB0015090D0
(en)
*
|
2000-06-20 |
2000-08-09 |
Implyx Ltd |
Gene-activating conjugates
|
US7026462B2
(en)
*
|
2000-12-07 |
2006-04-11 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
US7273923B2
(en)
*
|
2001-01-22 |
2007-09-25 |
Sangamo Biosciences, Inc. |
Zinc finger proteins for DNA binding and gene regulation in plants
|
US7067617B2
(en)
*
|
2001-02-21 |
2006-06-27 |
The Scripps Research Institute |
Zinc finger binding domains for nucleotide sequence ANN
|
US20050235369A1
(en)
*
|
2001-03-28 |
2005-10-20 |
Yen Choo |
Gene regulation II
|
EP1421177A4
(de)
*
|
2001-08-20 |
2006-06-07 |
Scripps Research Inst |
Zinkfinger-bindungsdomänen für cnn
|
AU2002365796A1
(en)
*
|
2001-12-07 |
2003-06-17 |
Toolgen, Inc. |
Phenotypic screen of chimeric proteins
|
US20040259258A1
(en)
*
|
2001-12-07 |
2004-12-23 |
Kim Jin-Soo |
Regulation of prokaryotic gene expression with zinc finger proteins
|
ATE347593T1
(de)
|
2002-01-23 |
2006-12-15 |
Univ Utah Res Found |
Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
|
WO2004018632A2
(en)
*
|
2002-08-23 |
2004-03-04 |
Sangamo Biosciences, Inc. |
High-throughput screen for modulators of chromatin modifying activity
|
US7361635B2
(en)
|
2002-08-29 |
2008-04-22 |
Sangamo Biosciences, Inc. |
Simultaneous modulation of multiple genes
|
EP1581610A4
(de)
|
2002-09-05 |
2009-05-27 |
California Inst Of Techn |
Verwendung chimerer nukleasen zur stimulierung des gen-targeting
|
WO2004099367A2
(en)
*
|
2002-10-23 |
2004-11-18 |
The General Hospital Corporation |
Methods for producing zinc finger proteins that bind to extended dna target sequences
|
WO2004046387A1
(en)
*
|
2002-11-15 |
2004-06-03 |
Sangamo Biosciences, Inc. |
Methods and compositions for analysis of regulatory sequences
|
US20060251643A1
(en)
*
|
2002-12-09 |
2006-11-09 |
Toolgen, Inc. |
Regulatory zinc finger proteins
|
CA2532200C
(en)
*
|
2003-07-31 |
2011-08-16 |
Kao Corporation |
Powder composition for paper manufacturing
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US20090312277A1
(en)
*
|
2004-11-19 |
2009-12-17 |
Abdelhadi Rebbaa |
Compositions And Methods For Reversing Or Preventing Resistance Of A Cancer Cell To A Cytotoxic Agent
|
JP2009520463A
(ja)
*
|
2005-11-28 |
2009-05-28 |
ザ スクリプス リサーチ インスティテュート |
Tnnのための亜鉛フィンガー結合ドメイン
|
US20070154989A1
(en)
*
|
2006-01-03 |
2007-07-05 |
The Scripps Research Institute |
Zinc finger domains specifically binding agc
|
US20070178499A1
(en)
*
|
2006-01-06 |
2007-08-02 |
The Scripps Research Institute |
Specific Labeling of Protein with Zinc Finger Tags and Use of Zinc-Finger-Tagged Proteins for Analysis
|
US20090305977A1
(en)
*
|
2006-02-09 |
2009-12-10 |
Sangamo Bioscience, Inc. |
Method for treating peripheral arterial disease with zinc finger proteins
|
AU2007254251A1
(en)
*
|
2006-05-19 |
2007-11-29 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inactivation of dihydrofolate reductase
|
WO2007139898A2
(en)
|
2006-05-25 |
2007-12-06 |
Sangamo Biosciences, Inc. |
Variant foki cleavage half-domains
|
JP5551432B2
(ja)
|
2006-05-25 |
2014-07-16 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
遺伝子不活性化のための方法と組成物
|
US8148129B2
(en)
*
|
2006-06-30 |
2012-04-03 |
The Regents Of The University Of California |
Generation of potent dominant negative transcriptional inhibitors
|
CN101883850B
(zh)
|
2007-07-12 |
2014-11-12 |
桑格摩生物科学股份有限公司 |
用于失活α-1,6岩藻糖基转移酶(FUT8)基因表达的方法和组合物
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
EP2188384B1
(de)
*
|
2007-09-27 |
2015-07-15 |
Sangamo BioSciences, Inc. |
Schnelle in-vivo-identifizierung von biologisch aktiven nukleasen
|
CN101878307B
(zh)
*
|
2007-09-27 |
2017-07-28 |
陶氏益农公司 |
以5‑烯醇式丙酮酰莽草酸‑3‑磷酸合酶基因为靶的改造锌指蛋白
|
CA2703045C
(en)
|
2007-10-25 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted integration
|
US8597912B2
(en)
|
2008-06-10 |
2013-12-03 |
Sangamo Biosciences, Inc. |
Methods and compositions for generation of Bax-and Bak-deficient cell lines
|
CA2734235C
(en)
|
2008-08-22 |
2019-03-26 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
JP5756016B2
(ja)
|
2008-10-29 |
2015-07-29 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
グルタミンシンセターゼ遺伝子の発現を不活性化する方法及び組成物
|
CA2745031C
(en)
|
2008-12-04 |
2018-08-14 |
Sangamo Biosciences, Inc. |
Genome editing in rats using zinc-finger nucleases
|
JP5827132B2
(ja)
|
2009-02-04 |
2015-12-02 |
サンガモ バイオサイエンシズ インコーポレイテッド |
ニューロパチーを治療するための方法および組成物
|
JP5932632B2
(ja)
|
2009-03-20 |
2016-06-15 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
改変された亜鉛フィンガータンパク質を使用したcxcr4の修飾
|
US9834787B2
(en)
*
|
2009-04-09 |
2017-12-05 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
EP2727600B1
(de)
|
2009-07-28 |
2019-03-27 |
Sangamo Therapeutics, Inc. |
Zinkfingerfusionsproteine zur supprimierung eines huntington gens
|
US8586526B2
(en)
|
2010-05-17 |
2013-11-19 |
Sangamo Biosciences, Inc. |
DNA-binding proteins and uses thereof
|
WO2011049627A1
(en)
|
2009-10-22 |
2011-04-28 |
Dow Agrosciences Llc |
Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
AU2011207769B2
(en)
*
|
2010-01-22 |
2015-05-28 |
Corteva Agriscience Llc |
Targeted genomic alteration
|
EP4328304A2
(de)
|
2010-02-08 |
2024-02-28 |
Sangamo Therapeutics, Inc. |
Manipulierte spaltungshalbdomänen
|
EP2660318A1
(de)
|
2010-02-09 |
2013-11-06 |
Sangamo BioSciences, Inc. |
Gezielte Genommodifikation mit partiell einzelsträngigen Donatormolekülen
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
US8772453B2
(en)
|
2010-05-03 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Compositions for linking zinc finger modules
|
CA2805442C
(en)
|
2010-07-21 |
2020-05-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of an hla locus
|
AU2011312562B2
(en)
|
2010-09-27 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
CA2814143C
(en)
|
2010-10-12 |
2020-09-08 |
The Children's Hospital Of Philadelphia |
Methods and compositions for treating hemophilia b
|
US9267123B2
(en)
|
2011-01-05 |
2016-02-23 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
EP3461896B1
(de)
|
2011-07-15 |
2023-11-29 |
The General Hospital Corporation |
Verfahren zur transkription einer aktivatorähnlichen effektoranordnung
|
EP3613852A3
(de)
|
2011-07-22 |
2020-04-22 |
President and Fellows of Harvard College |
Beurteilung und verbesserung einer nukleasespaltungsspezifität
|
CA2841541C
(en)
|
2011-07-25 |
2019-11-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
KR102209330B1
(ko)
|
2011-09-21 |
2021-01-29 |
상가모 테라퓨틱스, 인코포레이티드 |
이식 유전자 발현의 조절을 위한 방법 및 조성물
|
US9222105B2
(en)
|
2011-10-27 |
2015-12-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the HPRT locus
|
WO2013074999A1
(en)
|
2011-11-16 |
2013-05-23 |
Sangamo Biosciences, Inc. |
Modified dna-binding proteins and uses thereof
|
CA2865011C
(en)
|
2012-02-29 |
2021-06-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
KR102116153B1
(ko)
|
2012-05-07 |
2020-05-27 |
상가모 테라퓨틱스, 인코포레이티드 |
도입유전자의 뉴클레아제-매개 표적화된 통합을 위한 방법 및 조성물
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
EP2861737B1
(de)
|
2012-06-19 |
2019-04-17 |
Regents Of The University Of Minnesota |
Gen-targeting in pflanzen durch dns-viren
|
EP2872154B1
(de)
|
2012-07-11 |
2017-05-31 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur freisetzung von biologischen wirkstoffen
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
EP2872625B1
(de)
|
2012-07-11 |
2016-11-16 |
Sangamo BioSciences, Inc. |
Zusammensetzungen und verfahren zur behandlung von lysosomalen speicherkrankheiten
|
EP2890780B8
(de)
|
2012-08-29 |
2020-08-19 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur behandlung eines genetischen leidens
|
KR102357105B1
(ko)
|
2012-09-04 |
2022-02-08 |
더 스크립스 리서치 인스티튜트 |
표적화된 바인딩 특이도를 갖는 키메라 폴리펩타이드들
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
UA119135C2
(uk)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб отримання трансгенної рослини
|
CA2884162C
(en)
|
2012-09-07 |
2020-12-29 |
Dow Agrosciences Llc |
Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
US9597357B2
(en)
|
2012-10-10 |
2017-03-21 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
US20150267176A1
(en)
|
2012-10-12 |
2015-09-24 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
EP2929017A4
(de)
|
2012-12-05 |
2016-09-28 |
Sangamo Biosciences Inc |
Verfahren und zusammensetzungen zur regulierung von stoffwechselerkrankungen
|
WO2014089541A2
(en)
|
2012-12-07 |
2014-06-12 |
Haplomics, Inc. |
Factor viii mutation repair and tolerance induction
|
JP6445462B2
(ja)
|
2013-02-07 |
2018-12-26 |
ザ ジェネラル ホスピタル コーポレイション |
Tale転写活性化因子
|
ES2904803T3
(es)
|
2013-02-20 |
2022-04-06 |
Regeneron Pharma |
Modificación genética de ratas
|
WO2014130955A1
(en)
|
2013-02-25 |
2014-08-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
WO2014153470A2
(en)
|
2013-03-21 |
2014-09-25 |
Sangamo Biosciences, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
ES2699578T3
(es)
|
2013-04-16 |
2019-02-11 |
Regeneron Pharma |
Modificación direccionada del genoma de rata
|
JP2016518142A
(ja)
|
2013-05-10 |
2016-06-23 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法および組成物
|
US9873894B2
(en)
|
2013-05-15 |
2018-01-23 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
EP3008186B1
(de)
*
|
2013-06-14 |
2018-11-28 |
Cellectis |
Verfahren zur nichttransgenen genomänderung bei pflanzen
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
EP3988654A1
(de)
|
2013-08-28 |
2022-04-27 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur vernetzung von dna-bindungsdomänen und -spaltungsdomänen
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
CN110713995B
(zh)
|
2013-10-17 |
2023-08-01 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
EP3057432B1
(de)
|
2013-10-17 |
2018-11-21 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen für nukleasevermitteltes genom-engineering in hämotopoietischen stammzellen
|
UA121459C2
(uk)
|
2013-11-04 |
2020-06-10 |
Дау Агросаєнсиз Елелсі |
Рекомбінантна молекула нуклеїнової кислоти для трансформації рослини сої
|
EP3066110B1
(de)
|
2013-11-04 |
2021-12-29 |
Corteva Agriscience LLC |
Optimale maispflanzen
|
BR102014027436B1
(pt)
|
2013-11-04 |
2022-06-28 |
Dow Agrosciences Llc |
Molécula de ácido nucleico recombinante, e método para a produção de uma célula vegetal transgênica
|
JP6633532B2
(ja)
|
2013-11-04 |
2020-01-22 |
ダウ アグロサイエンシィズ エルエルシー |
最適なトウモロコシ遺伝子座
|
CN111218447A
(zh)
|
2013-11-07 |
2020-06-02 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
EP3068905A4
(de)
|
2013-11-11 |
2017-07-05 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur behandlung der huntington-krankheit
|
PT3492593T
(pt)
|
2013-11-13 |
2021-10-18 |
Childrens Medical Center |
Regulação da expressão de genes mediada por nucleases
|
CN105940013B
(zh)
|
2013-12-09 |
2020-03-27 |
桑格摩生物科学股份有限公司 |
用于治疗血友病的方法和组合物
|
KR102170502B1
(ko)
|
2013-12-11 |
2020-10-28 |
리제너론 파마슈티칼스 인코포레이티드 |
게놈의 표적화된 변형을 위한 방법 및 조성물
|
PT3080279T
(pt)
|
2013-12-11 |
2018-12-17 |
Regeneron Pharma |
Métodos e composições para a modificação direcionada de um genoma
|
US20150166985A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting von willebrand factor point mutations
|
SI3102673T1
(sl)
|
2014-02-03 |
2020-11-30 |
Sangamo Therapeutics, Inc. |
Postopki in sestavki za zdravljenje beta talasemije
|
WO2015127439A1
(en)
|
2014-02-24 |
2015-08-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
EP3929279A1
(de)
|
2014-03-18 |
2021-12-29 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur regulierung der zinkfingerproteinexpression
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
CN106413760B
(zh)
|
2014-05-08 |
2020-01-14 |
桑格摩生物科学股份有限公司 |
用于治疗亨廷顿病的方法和组合物
|
WO2015175642A2
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
EP3152319A4
(de)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur nukleasekonstruktion
|
LT3152312T
(lt)
|
2014-06-06 |
2020-04-27 |
Regeneron Pharmaceuticals, Inc. |
Tikslinio lokuso modifikavimo būdai ir kompozicijos
|
JP6336140B2
(ja)
|
2014-06-23 |
2018-06-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
ヌクレアーゼ媒介dnaアセンブリ
|
PL3161128T3
(pl)
|
2014-06-26 |
2019-02-28 |
Regeneron Pharmaceuticals, Inc. |
Sposoby i kompozycje do celowanych modyfikacji genetycznych i sposoby zastosowania
|
MX2017000555A
(es)
|
2014-07-14 |
2017-08-10 |
Univ Washington State |
Desactivacion de nanos que produce ablacion de celulas de linea germinal.
|
US10738278B2
(en)
|
2014-07-15 |
2020-08-11 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
US9816074B2
(en)
|
2014-07-25 |
2017-11-14 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
CA2956224A1
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
CN113699113A
(zh)
|
2014-09-16 |
2021-11-26 |
桑格摩治疗股份有限公司 |
用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
|
AU2015332451A1
(en)
|
2014-10-15 |
2017-04-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for generating or maintaining pluripotent cells
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
MX2017008190A
(es)
|
2014-12-19 |
2018-03-23 |
Regeneron Pharma |
Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa.
|
EP3247366A4
(de)
|
2015-01-21 |
2018-10-31 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur identifizierung hochspezifischer nukleasen
|
EP4335918A3
(de)
|
2015-04-03 |
2024-04-17 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzung und verfahren zur genomeditierung von b-zellen
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
MX2017014446A
(es)
|
2015-05-12 |
2018-06-13 |
Sangamo Therapeutics Inc |
Regulacion de expresion genica mediada por nucleasa.
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
CA2991301A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
FI3331355T3
(fi)
|
2015-08-06 |
2024-06-17 |
Univ Missouri |
Sikojen lisääntymishäiriö- ja keuhkotulehdusoireyhtymävirukselle (PRRSV) resistentti sika ja soluja, joilla on muokattuja CD163-geenejä
|
US11606940B2
(en)
|
2015-08-07 |
2023-03-21 |
Commonwealth Scientific And Industrial Research Organisation |
Method for producing an animal comprising a germline genetic modification
|
IL258030B
(en)
|
2015-09-23 |
2022-08-01 |
Sangamo Therapeutics Inc |
Htt suppressing factors and their uses
|
US20190225955A1
(en)
|
2015-10-23 |
2019-07-25 |
President And Fellows Of Harvard College |
Evolved cas9 proteins for gene editing
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
AU2016343887B2
(en)
|
2015-10-28 |
2023-04-06 |
Sangamo Therapeutics, Inc. |
Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
|
EP3380622A4
(de)
|
2015-11-23 |
2019-08-07 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zum immunitäts-engineering
|
US10907133B2
(en)
|
2015-11-24 |
2021-02-02 |
Commonwealth Scientific And Industrial Research Organisation |
Production of viruses in avian eggs
|
US11174466B2
(en)
|
2015-11-24 |
2021-11-16 |
Commonwealth Scientific And Industrial Research Organisation |
Production of viruses in cell culture
|
BR112018012235A2
(pt)
|
2015-12-18 |
2018-12-04 |
Sangamo Therapeutics Inc |
rompimento alvejado do receptor de células de mhc
|
CA3008413A1
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the t cell receptor
|
US20170202931A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
JP7012650B2
(ja)
|
2016-02-02 |
2022-01-28 |
サンガモ セラピューティクス, インコーポレイテッド |
Dna結合ドメインと切断ドメインとを連結するための組成物
|
AU2017268842B2
(en)
|
2016-05-27 |
2022-08-11 |
Aadigen, Llc |
Peptides and nanoparticles for intracellular delivery of genome-editing molecules
|
AU2017295720B2
(en)
|
2016-07-13 |
2021-07-22 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
JP2019523009A
(ja)
|
2016-07-29 |
2019-08-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
C末端切断型フィブリリン−1の発現をもたらす変異を有するマウス
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
SG10201913948PA
(en)
|
2016-08-24 |
2020-03-30 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
PE20190568A1
(es)
|
2016-08-24 |
2019-04-22 |
Sangamo Therapeutics Inc |
Regulacion de la expresion genica usando nucleasas modificadas
|
US10960085B2
(en)
|
2016-09-07 |
2021-03-30 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
EP3523422A1
(de)
|
2016-10-05 |
2019-08-14 |
FUJIFILM Cellular Dynamics, Inc. |
Erzeugung reifer linien aus induzierten pluripotenten stammzellen mit mecp2-unterbrechung
|
BR112019006652A2
(pt)
|
2016-10-13 |
2019-07-02 |
Juno Therapeutics Inc |
métodos e composições para imunoterapia envolvendo moduladores da via metabólica do triptofano
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
WO2018075736A1
(en)
|
2016-10-20 |
2018-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of fabry disease
|
CA3041668A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
WO2018102665A1
(en)
|
2016-12-01 |
2018-06-07 |
Sangamo Therapeutics, Inc. |
Tau modulators and methods and compositions for delivery thereof
|
WO2018102612A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
JP7416406B2
(ja)
|
2016-12-08 |
2024-01-17 |
ケース ウェスタン リザーブ ユニバーシティ |
機能的ミエリン産生を増進させるための方法および組成物
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
BR112019014841A2
(pt)
|
2017-01-23 |
2020-04-28 |
Regeneron Pharma |
rna guia, uso do rna guia, rna antissentido, sirna ou shrna, uso do rna antissentido, do sirna ou do shrna, ácido nucleico isolado, vetor, composição, célula, e, métodos para modificar um gene hsd17b13 em uma célula, para diminuir a expressão de um gene hsd17b13 em uma célula, para modificar uma célula e para tratar um indivíduo que não é portador da variante de hsd17b13
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
EP3592853A1
(de)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Unterdrückung von schmerzen durch geneditierung
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
IL269458B2
(en)
|
2017-03-23 |
2024-02-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
US11913015B2
(en)
|
2017-04-17 |
2024-02-27 |
University Of Maryland, College Park |
Embryonic cell cultures and methods of using the same
|
CA3061612A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
RU2019139045A
(ru)
|
2017-05-03 |
2021-06-03 |
Сангамо Терапьютикс, Инк. |
Способы и композиции для модификации гена регулятора трансмембранной проводимости при кистозном фиброзе (cftr)
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
AU2018302098A1
(en)
|
2017-07-18 |
2020-02-20 |
Csl Behring Gene Therapy, Inc. |
Compositions and methods for treating beta-hemoglobinopathies
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
AU2018325363A1
(en)
|
2017-08-29 |
2020-04-09 |
Global Crop Innovations Pty. Ltd. |
Improved BLue Aleurone and other segregation systems
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
US20190098879A1
(en)
|
2017-09-29 |
2019-04-04 |
Regeneron Pharmaceuticals, Inc. |
Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use
|
EP3697906A1
(de)
|
2017-10-16 |
2020-08-26 |
The Broad Institute, Inc. |
Verwendungen von adenosinbasiseditoren
|
CA3079748A1
(en)
|
2017-11-09 |
2019-05-16 |
Sangamo Therapeutics, Inc. |
Genetic modification of cytokine inducible sh2-containing protein (cish) gene
|
US20200361877A1
(en)
|
2018-01-17 |
2020-11-19 |
Vertex Pharmaceuticals Incorporated |
Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
AU2019209290B2
(en)
|
2018-01-17 |
2024-03-07 |
Vertex Pharmaceuticals Incorporated |
DNA-PK inhibitors
|
BR112020014315A2
(pt)
|
2018-01-17 |
2020-12-08 |
Vertex Pharmaceuticals Incorporated |
Inibidores de dna-pk
|
EP3749350A4
(de)
|
2018-02-08 |
2021-12-01 |
Sangamo Therapeutics, Inc. |
Genetisch manipulierte zielspezifische nukleasen
|
JP7338893B2
(ja)
|
2018-03-20 |
2023-09-05 |
チンホワ ユニバーシティ |
アルツハイマー病動物モデルおよびその使用
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
CA3095084A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
CN112313246A
(zh)
|
2018-04-18 |
2021-02-02 |
桑格摩生物治疗股份有限公司 |
用于调节亨廷顿蛋白(htt)的锌指蛋白组合物
|
CA3100034A1
(en)
|
2018-05-11 |
2019-11-14 |
Beam Therapeutics Inc. |
Methods of editing single nucleotide polymorphism using programmable base editor systems
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
JP2021536229A
(ja)
|
2018-08-23 |
2021-12-27 |
サンガモ セラピューティクス, インコーポレイテッド |
操作された標的特異的な塩基エディター
|
US20210348177A1
(en)
|
2018-09-05 |
2021-11-11 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
JP2022500052A
(ja)
|
2018-09-18 |
2022-01-04 |
サンガモ セラピューティクス, インコーポレイテッド |
プログラム細胞死1(pd1)特異的ヌクレアーゼ
|
US20220389395A1
(en)
|
2018-10-29 |
2022-12-08 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
US20220282275A1
(en)
|
2018-11-15 |
2022-09-08 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
US20220023348A1
(en)
|
2018-11-28 |
2022-01-27 |
Forty Seven, Inc. |
Genetically modified hspcs resistant to ablation regime
|
JP7449291B2
(ja)
|
2018-12-20 |
2024-03-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヌクレアーゼ媒介リピート伸長
|
WO2020146805A1
(en)
|
2019-01-11 |
2020-07-16 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
WO2020163017A1
(en)
|
2019-02-06 |
2020-08-13 |
Klogenix Llc |
Dna binding proteins and uses thereof
|
AU2019428629A1
(en)
|
2019-02-06 |
2021-01-28 |
Sangamo Therapeutics, Inc. |
Method for the treatment of mucopolysaccharidosis type I
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
WO2020181193A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
MX2021011426A
(es)
|
2019-03-19 |
2022-03-11 |
Broad Inst Inc |
Metodos y composiciones para editar secuencias de nucleótidos.
|
MX2021012152A
(es)
|
2019-04-02 |
2021-11-03 |
Sangamo Therapeutics Inc |
Metodos para el tratamiento de beta-talasemia.
|
JP2022527809A
(ja)
|
2019-04-03 |
2022-06-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗体コード配列をセーフハーバー遺伝子座に挿入するための方法および組成物
|
US11737435B2
(en)
|
2019-04-04 |
2023-08-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized coagulation factor 12 locus
|
AU2020253531C1
(en)
|
2019-04-04 |
2022-06-16 |
Regeneron Pharmaceuticals, Inc. |
Methods for scarless introduction of targeted modifications into targeting vectors
|
CN113966401A
(zh)
|
2019-04-10 |
2022-01-21 |
犹他大学研究基金会 |
用于治疗amd的htra1调节
|
US20220307003A1
(en)
|
2019-04-17 |
2022-09-29 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
BR112021021200A2
(pt)
|
2019-05-01 |
2021-12-21 |
Juno Therapeutics Inc |
Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
|
MX2021013219A
(es)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos.
|
JP2022534867A
(ja)
|
2019-06-04 |
2022-08-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ベータスリップ変異を有するヒト化ttr遺伝子座を含む非ヒト動物と使用方法
|
AU2020289581A1
(en)
|
2019-06-07 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized albumin locus
|
AU2020290509A1
(en)
|
2019-06-14 |
2021-11-11 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
US20220267732A1
(en)
|
2019-08-01 |
2022-08-25 |
Sana Biotechnology, Inc. |
Dux4 expressing cells and uses thereof
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
AU2020336302A1
(en)
|
2019-08-23 |
2022-03-03 |
Sana Biotechnology, Inc. |
CD24 expressing cells and uses thereof
|
AU2020376048A1
(en)
|
2019-11-01 |
2022-06-02 |
Sangamo Therapeutics, Inc. |
Compositions and methods for genome engineering
|
US20210130828A1
(en)
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Gin recombinase variants
|
MX2022005572A
(es)
|
2019-11-08 |
2022-06-09 |
Regeneron Pharma |
Estrategias crispr y aav para la terapia de retinosquisis juvenil ligada al cromosoma x.
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
US20230086199A1
(en)
|
2019-11-26 |
2023-03-23 |
The Broad Institute, Inc. |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
WO2021158921A2
(en)
|
2020-02-05 |
2021-08-12 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
AU2021232598A1
(en)
|
2020-03-04 |
2022-09-08 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for sensitization of tumor cells to immune therapy
|
BR112022019060A2
(pt)
|
2020-03-25 |
2022-11-29 |
Sana Biotechnology Inc |
Células neurais hipoimunogênicas para o tratamento de distúrbios e condições neurológicas
|
EP4143315A1
(de)
|
2020-04-28 |
2023-03-08 |
The Broad Institute Inc. |
<smallcaps/>?ush2a? ?gezielte basisbearbeitung eines thegens
|
CN115803435A
(zh)
|
2020-05-06 |
2023-03-14 |
塞勒克提斯公司 |
用于在细胞基因组中靶向插入外源序列的方法
|
EP4146284A1
(de)
|
2020-05-06 |
2023-03-15 |
Cellectis S.A. |
Verfahren zur genetischen modifizierung von zellen zur freisetzung therapeutischer proteine
|
JP2023525304A
(ja)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート,インコーポレーテッド |
標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
|
CN115835873A
(zh)
|
2020-05-13 |
2023-03-21 |
朱诺治疗学股份有限公司 |
用于产生表达重组受体的供体分批细胞的方法
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
CN116234558A
(zh)
|
2020-06-26 |
2023-06-06 |
朱诺治疗学有限公司 |
条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
|
CA3189338A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
AU2021325941A1
(en)
|
2020-08-13 |
2023-03-09 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
EP4204545A2
(de)
|
2020-08-25 |
2023-07-05 |
Kite Pharma, Inc. |
T-zellen mit verbesserter funktionalität
|
KR20230090367A
(ko)
|
2020-11-04 |
2023-06-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법
|
CN117042600A
(zh)
|
2020-11-16 |
2023-11-10 |
猪改良英国有限公司 |
具有经编辑的anp32基因的抗甲型流感动物
|
KR20230137900A
(ko)
|
2020-12-31 |
2023-10-05 |
사나 바이오테크놀로지, 인크. |
Car-t 활성을 조정하기 위한 방법 및 조성물
|
EP4263825A1
(de)
|
2021-02-19 |
2023-10-25 |
Beam Therapeutics, Inc. |
Rekombinante tollwutviren für gentherapie
|
CN118019546A
(zh)
|
2021-03-23 |
2024-05-10 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途
|
KR20240013135A
(ko)
|
2021-05-27 |
2024-01-30 |
사나 바이오테크놀로지, 인크. |
조작된 hla-e 또는 hla-g를 포함하는 저면역원성 세포
|
EP4370544A2
(de)
|
2021-07-14 |
2024-05-22 |
Sana Biotechnology, Inc. |
Veränderte expression von y-chromosom-gebundenen antigenen in hypoimmunogenen zellen
|
KR20240073006A
(ko)
|
2021-08-11 |
2024-05-24 |
사나 바이오테크놀로지, 인크. |
동종이계 세포 요법을 위한 유전자 변형된 1차 세포
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
CA3227613A1
(en)
|
2021-08-11 |
2023-02-16 |
William Dowdle |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
WO2023023553A2
(en)
*
|
2021-08-17 |
2023-02-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions, systems, and methods for activating and silencing gene expression
|
WO2023039468A1
(en)
|
2021-09-08 |
2023-03-16 |
Beam Therapeutics Inc. |
Viral guide rna delivery
|
WO2023069790A1
(en)
|
2021-10-22 |
2023-04-27 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
CA3241438A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
AU2022424002A1
(en)
|
2021-12-29 |
2024-06-13 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023220035A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
WO2023220043A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024031053A1
(en)
|
2022-08-05 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Aggregation-resistant variants of tdp-43
|
WO2024040083A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|